Atos Medical acquired by PAI Partners
Context
PAI Partners has entered into a definitive agreement to acquire 100% of Atos Medical from EQT. This secondary LBO represents the 10th investment of the PAI Europe VI fund and marks the exit of EQT, which had overseen a period where the company doubled in size within five years. The current management team, led by CEO Claus Bjerre, remains in place to lead the next phase of the company's development under PAI's sponsorship. The strategic rationale for the acquisition is centered on the underpenetrated nature of the global laryngectomy market and the scalability of Atos Medical's direct-to-consumer model. PAI intends to leverage its healthcare sector capabilities to accelerate the company's transformational strategy, focusing on increased R&D investment and a broader global sales footprint. The deal is underpinned by the target's exceptional financial performance, including a 30% revenue growth in 2015 and industry-leading margins.
The acquisition of Atos Medical is part of the growth strategy of PAI Partners, which already has several external growth operations under its belt, notably Groupe B&B Hotels in 2015.
Atos Medical, which reported an EBITDA margin of [members only] in 2016, is valued in this transaction at an EV/EBITDA multiple of 10x–18x.
-> Deep-dive in Healthcare & Pharma market trends
Target
Founded in 1986, Atos Medical is the global market leader in laryngectomy care, specialized in supporting patients living with a neck stoma. The company’s core business model focuses on restoring speaking ability and improving pulmonary health for patients who have undergone surgical removal of the voice box or tracheostomy procedures. Its value proposition is built on a unique direct-to-consumer (DTC) model, which accounts for approximately 50% of its laryngectomy revenues, ensuring personalized care and long-term patient engagement. Atos Medical’s strategy emphasizes clinical innovation and geographical expansion, providing high-quality medical consumables such as heat and moisture exchangers (HMEs) and voice prostheses. By diversifying into the tracheostomy segment through selective acquisitions, the company has established itself as a comprehensive Ear, Nose, and Throat (ENT) specialist. With a direct presence in 30 countries and a distribution network reaching ~90 markets, Atos Medical combines technical medical expertise with a patient-centric service layer to maintain industry-leading margins and high organic growth.
Ent. Value
€500M–1.5bn
Equity Value
[members only]
Multiples
EV / Revenue
4x–10x
EV / EBITDA
10x–18x
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with Atos Medical
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 11/2021 | COLOPLAST | ATOS MEDICAL | SWEDEN | Medical Consumables |
Other operations with PAI Partners
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 10/2017 | PAI PARTNERS | REFRESCO | NETHERLANDS | Beverages |
| 05/2017 | PAI PARTNERS | ELITECH GROUP | FRANCE | Diagnostic Equipment |
| 06/2016 | PAI PARTNERS | ETHYPHARM | FRANCE | Pharma & Biotech |
| 02/2016 | ADB SAFEGATE / PAI PARTNERS | SAFEGATE INTERNATIONAL | SWEDEN | Aerospace, Naval & Defense |
| 12/2015 | PAI PARTNERS | GROUPE B&B HOTELS | FRANCE | Hotels & Accommodation |
| 06/2014 | PAI PARTNERS | DOMUSVI | FRANCE | Nursing Homes |
| 06/2014 | PAI PARTNERS | VPS HOLDINGS | UNITED KINGDOM | Security & Guarding |
| 06/2014 | PAI PARTNERS | LABEYRIE FINE FOODS | FRANCE | Food Products |
| 04/2014 | PAI PARTNERS / THE CARLYLE GROUP | INNOVISTA (EX CST) | FRANCE | Sensors & Optics |
| 04/2014 | PAI PARTNERS | EURO MEDIA GROUP | FRANCE | Audiovisual Production |
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 09/2016 | ARCHIMED | POLYPLUS | FRANCE | R&D Biotech |
| 09/2016 | ARDIAN / IXO PRIVATE EQUITY | LAGARRIGUE | FRANCE | Implants & Prosthetics |
| 06/2016 | PAI PARTNERS | ETHYPHARM | FRANCE | Pharma & Biotech |
| 06/2016 | BRIDGEPOINT / RAISE / FLEXSTONE PARTNERS | ACTEON | FRANCE | Medical Devices |
| 05/2016 | IK PARTNERS | MARLE GROUP | FRANCE | Implants & Prosthetics |
| 03/2016 | PSP INVESTMENTS | ANTELLIQ | FRANCE | Animal Health |
| 03/2016 | CVC | DOC GENERICI | ITALY | Generics / Labs |
| 02/2016 | TE CONNECTIVITY | CREGANNA MEDICAL | IRELAND | Medical Devices |
| 02/2016 | ASTORG / GOLDMAN SACHS | HRA PHARMA | FRANCE | Generics / Labs |
| 07/2015 | PERRIGO COMPANY | NATURWOHL PHARMA (YOKEBE) | GERMANY | Generics / Labs |
REFERENCES
Valuation range: EV €500M–1.5bn
Revenue range: €100–200M
EBITDA range: €50–100M
EV/Revenue range: 4x - 10x
EV/EBITDA range: 10x - 18x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Atos Medical by PAI Partners are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Target: atos medical
FAQ
What transaction does this page cover?
How was the acquisition of Atos Medical by PAI Partners valued, and what multiples were paid?
What were Atos Medical’s revenue and EBITDA at the time of the deal?
What sources support the information on this transaction?
What is mynth?